Heidi Glosli

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (6)

• Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐PROTECT Main Study
  European Journal of Haematology 2026 DOI: 10.1111/ejh.70078
  +Save
• Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐PROTECT Main Study
  European Journal of Haematology 2026 DOI: 10.1111/ejh.70059
  +Save
• Immune Tolerance Induction With a Recombinant Factor VIII Fc in Haemophilia A: Data From a Chart Review Study
  European Journal of Haematology 2025 DOI: 10.1111/ejh.14427
  +Save
• Time to broaden the eligibility criteria in paediatric oncology trials? An analysis of patients with rhabdomyosarcoma non-eligible to the EpSSG RMS2005 trial
  EJC Paediatric Oncology 2023 DOI: 10.1016/j.ejcped.2023.100014
  +Save
• Localised rhabdomyosarcoma in infants (<12 months) and young children (12–36 months of age) treated on the EpSSG RMS 2005 study
  European Journal of Cancer 2022 DOI: 10.1016/j.ejca.2021.10.031
  +Save
• Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) – RMS2005 study
  European Journal of Cancer 2021 DOI: 10.1016/j.ejca.2021.04.007
  +Save